You are viewing the site in preview mode
Skip to main content
|
Systemic therapy for MTC n = 98
|
n (%)
|
|---|
|
Metastatic disease at presentation (%)
|
12 (12)
|
|
Developed unresectable recurrence or metastatic disease (%)
|
25 (26)
|
|
Received systemic therapy for unresectable or metastatic MTC (%)
|
7/37 (19)
|
|
Systemic therapy givena – no.
| |
|
Sunitinib
|
3
|
|
Sorafenib
|
2
|
|
Vandetanib
|
3
|
|
Temsirolimus
|
1
|
|
Doxorubicin
|
2
|
|
Death due to MTC – no. (%)
|
27 (28)
|
|
Prescribed TKI
|
2
|
|
Prescribed doxorubicin
|
2
|
|
Discussed TKI but did not receive therapy
|
5
|
|
TKI available but never discussed
|
1
|
|
TKI not available
|
17
|
-
aSome patients received 2 or more lines of systemic therapy and are still alive on treatment
